Icariin in Male Reproduction: Multi-Target Pharmacological Mechanisms and Therapeutic Potential

A narrative review maps how icariin, horny goat weed's active compound, may improve sperm function — mostly in rodents

Journal: European Journal of Pharmacology | Published: 2026-02-26 | Type: Review | PMID: 41763476 Authors: Ran Feixue, Yu Yuan, Jiang Zhou, Liang Xin (Reproductive & Women-Children Hospital, Chengdu University of Traditional Chinese Medicine; NHC Key Laboratory of Chronobiology, Sichuan University — all TCM-affiliated institutions) Funding/COI: Funding not disclosed. Authors declare no competing financial interests.

Summary

Icariin (ICA) is the primary bioactive flavonoid in Epimedium, the plant behind "horny goat weed" supplements. This narrative review surveys preclinical and some clinical literature to argue that ICA improves male reproductive function via three broad mechanisms: reducing oxidative stress, modulating sex hormone biosynthesis, and shifting the apoptosis/proliferation balance in testicular cells. The paper provides no new data — it synthesizes existing research and proposes a "theoretical framework" for future translational work.

Claims

• ICA regulates redox homeostasis in testicular tissue, reducing oxidative damage to spermatogenic cells
• ICA modulates the HPG axis, influencing LH, FSH, and testosterone biosynthesis (mechanism not quantified in the abstract)
• ICA shifts the balance between apoptosis and proliferation in spermatocytes and Sertoli cells
• ICA may enhance outcomes in assisted reproductive technology when used as adjunct therapy
• Combination with "pharmacological agents or biotechnological approaches" could boost efficacy (no specific agents or effect sizes named)

Study Quality

This is a narrative review, the weakest tier of evidence synthesis. The authors did not register a protocol, report a systematic search strategy, or conduct meta-analysis — meaning study selection is at their discretion and the conclusions are not reproducible. MeSH terms include "Animals," confirming the bulk of underlying evidence is rodent or in vitro data. The abstract offers no quantitative effect estimates, no clinical trial citations, and no breakdown of how many human studies vs. animal studies contributed to each claim.

The authorship is entirely from TCM-affiliated institutions in Chengdu. That is not disqualifying, but it is a conflict-of-credibility situation: researchers with institutional mandates to validate traditional Chinese medicine reviewing evidence for a TCM compound, without listing funding sources.

Red Flags

• No funding disclosure — in a paper from an academic medical institution, this is an omission, not an answer
• Narrative review with no search methodology — cherry-picking risk is high and unmitigated
• Animal-heavy evidence base — the claims read as human-applicable conclusions drawn largely from rodent data
• No effect sizes in the abstract — a review that cannot summarize its own magnitude findings is a concern
• TCM framing throughout — terms like "Kidney deficiency syndrome" and "tonifying the Yang" are not translatable to evidence-based endpoints; they suggest the review is framed to validate a tradition rather than test a compound
• Speculative language — "may also be used," "theoretical framework," "translational research direction" — this is a hypothesis paper dressed as a review

Strengths

• Icariin is a real, structurally characterized compound (a prenylated flavonoid) with plausible pharmacological activity — this is not homeopathy
• Reviewing multi-target mechanisms is legitimate groundwork for future drug development
• Published in a peer-reviewed pharmacology journal with standard editorial oversight

Verdict

This paper is a literature survey from a TCM institution arguing that a supplement compound deserves more research. The underlying biochemistry of icariin is real and worth investigating, but this review does not advance that case meaningfully — no new data, no quantitative synthesis, no clinical effect sizes, no funding transparency, and a framing that leans on TCM tradition rather than mechanistic rigor. File it under "hypothesis-generating background reading," not evidence. Anyone designing a clinical trial on icariin would need to go back to the primary studies this review summarizes.